Dr. Reddy’s Laboratories announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. For Q2FY27, the company reported revenues of ₹86.7 billion and profit attributable to equity holders of ₹9.25 billion. The H1FY27 results showed revenues of ₹167.4 billion and a profit of ₹13.68 billion. The Board of Directors also approved these results, prepared under IFRS and Indian Accounting Standards.
Dr. Reddy’s Announces Q2 and H1 FY27 Financial Results
Dr. Reddy’s Laboratories Ltd. has released its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors, at their meeting on October 23, 2026, considered and approved these results.
Key Financial Highlights for Q2FY27:
- Revenues: ₹86,708 million (down 1.5% YoY; up 7.4% QoQ)
- Gross Margin: 52.1%
- EBITDA: ₹17,828 million (20.6% of Revenues)
- Profit before Tax: ₹12,277 million (14.2% of Revenues)
- Profit after Tax attributable to Equity Holders: ₹9,250 million (10.7% of Revenues)
Key Financial Highlights for H1FY27:
- Revenues: ₹167,413 million (down 3.5% YoY)
- Gross Margin: 49.4%
- EBITDA: ₹27,915 million (16.7% of Revenues)
- Profit before Tax: ₹17,803 million (10.6% of Revenues)
- Profit after Tax attributable to Equity Holders: ₹13,685 million (8.2% of Revenues)
The results were prepared in compliance with International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS). The company also announced a press release detailing these unaudited financial results.
Other Approvals and Information
The Board also approved the unaudited standalone financial results for the same period. Limited Review Reports from the Statutory Auditors on these results have also been completed.
The Board Meeting commenced at 3:00 p.m. IST and concluded at 4:38 p.m. IST.
Source: BSE
